A Chinese analysis of prescription anti-obesity medications has added to evidence that people who use popular GLP-1 drugs such as Ozempic to shed pounds face the prospect of “significant” weight rebound once they stop using them – challenges similar to those presented by more traditional slimming strategies.
Patients saw “significant weight” return eight weeks after anti-obesity medications (AOMs) were stopped, which continued after 20 weeks, the team from Peking University People’s Hospital wrote in an article published in the peer-reviewed journal BMC Medicine on Tuesday.
“Weight regain is common in various weight-loss strategies and it is necessary to establish long-term anti-obesity treatment in clinical practice,” the researchers said.
Worldwide, 2½ billion adults were overweight in 2022 and 890 million of them were obese, according to the World Health Organization.
01:20
China approves popular weight-loss drug Wegovy produced by Danish firm Novo Nordisk
China approves popular weight-loss drug Wegovy produced by Danish firm Novo Nordisk
Obesity can increase the risk of type 2 diabetes, heart disease and certain cancers. It can also negatively impact bone health and reproduction.
